Nonvenereal Syphilis Treatment Market Analysis

Treatment (Antibiotics, Topical Treatment)

The global nonvenereal syphilis treatment market is segmented and analyzed for demand and supply by treatment into antibiotics and topical treatment. Out of these segments, the antibiotics segment is estimated to gain the largest market share in the year 2035. The major factors applicable to the growth of the segment include the rapidly developing spectrum of antibiotics for the treatment of various bacterial pathogens-related infections worldwide. As per the Centers for Disease Control and Prevention (CDC), antibiotics such as Benzathine penicillin G can cure the early stages of syphilis with a single injection. CDC recommends 3 doses of long-acting Benzathine penicillin G at weekly intervals for latent syphilis of unknown duration. Moreover, Azithromycin as a single 2-g oral dose is found to be effective for treating primary and secondary syphilis among certain populations. Hence, the increasing need for the development of more such antibiotics along with the skyrocketing pharma research and development (R&D) research & development is expected to propel the antibiotics segment growth in the projected period. It was found that R&D spending in the pharmaceutical industry amounted to ~USD 238 billion globally in 2021.

Diagnosis (Lesions Testing, Dark-Field Microscopy)

The global nonvenereal syphilis treatment market is also segmented and analyzed for demand and supply by diagnosis into lesions testing, dark-field microscopy, and others. Amongst these segments, the lesion testing segment is expected to garner a significant share in the year 2035. The major factors applicable to the growth of the segment include the rising number of infection-related deaths worldwide as well as the increasing prevalence of genital ulcers disease (GUD) and the rising need to test nonvenereal genital lesions such as vitiligo, pearly penile papule, fixed drug eruptions, scabies, scrotal dermatitis, lichen planus besides other genital dermatoses such as sebaceous cyst, psoriasis, lichen sclerosus, plasma cell balanitis or Zoon's balanitis, granuloma annulare, lichen nitidus, lymphangioma circumscriptum, Paulo-necrotic tuberculid, squamous cell carcinoma, and tinea infections as they are spreading at a faster pace. It was found that infection-related deaths globally reached nearly 13·7 million deaths in 2019. All these factors are driving the rising investment in the development of accurate lesion testing, lesion biopsy, and skin biopsy techniques, expanding the scope of segment growth.

Our in-depth analysis of the global market includes the following segments: